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Abstract 
Health care providers are consistently unaware of the implications, efficacy, and 
resources correlated with medical cannabis and cannabidiol.  Thus, patients are 
uninformed about medical cannabis as a treatment option for their qualifying conditions.  
Informative educational sessions present a method to facilitate specialty knowledge 
development regarding medical cannabis and cannabidiol.  In this scholarly project, six 
nurse practitioners and two allied staff members, attended a PowerPoint presentation 
followed by an open discussion regarding cannabinoids.  Examination of post-
presentation survey results indicated that felt more informed about the physiology and 
efficacy of cannabidiol, more aware of the resources for them, and had increased comfort 
speaking and informing their patients about cannabidiol after the educational session.  
These results indicate that health care providers’ increased knowledge and awareness 
about medical cannabis and cannabidiol translates into increased comfort recommending 
cannabidiol in their patient’s treatment plan.  Future implications include continued 
education to health care providers in different demographics, to expand awareness of 
medical cannabis and cannabidiol and their associated implications to wellness. 
 Keywords: health care providers, medical cannabis, cannabinoids, education 
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1 
Education for Health Care Providers: Medical Cannabis 
Chapter One: Introduction 
In 2014, Minnesota legalized medical cannabis (MC). Since its inception, many 
patients with qualifying conditions have pursued MC for alleviating their symptoms; 
however, barriers continue for patients and healthcare providers (HCP) alike. Generally, 
HCP are not knowledgeable about the efficacy and validity of MC as a treatment option 
or are unaware of the process as to how to qualify their patients for the program.  
Consequently, patients seeking MC to assist in managing their symptoms are unable to 
receive certification or they are unaware of the benefits of MC and may continue to suffer 
from their symptoms because their HCP do not offer MC as a treatment option.  
Moreover, a lack of awareness and knowledge on behalf of HCP should not limit patients' 
ability to receive the benefits of MC to help manage their conditions.  To assist HCP in 
overcoming these barriers, an educational session with a focus on increasing HCP’ 
awareness regarding MC could positively influence the medical community, thus the aim 
of this scholarly project.  This chapter will address the foundation of this scholarly 
project by identifying the problem statement, the purpose of the scholarly project, clinical 
question, professional objectives, significance of the project, and an introduction to the 
doctoral essentials and competencies. 
Problem Statement 
Due to the differences in legality among states about MC and cannabidiol (CBD), 
HCP may be unaware of the implications, efficacy, and resources correlated with MC and 
CBD. Therefore, patients do not receive information or guidance about MC as a 
treatment option for their qualifying conditions.   
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Purpose of the Scholarly Project 
The purpose of this scholarly project is to identify knowledge gaps regarding MC 
and provide education to HCP in southern Minnesota regarding the significance, efficacy, 
and resources available, to incorporate MC into their practice. 
Clinical Question 
Does an educational session targeted to HCP in southeast Minnesota or 
Wisconsin, regarding the efficacy and implications of MC increase awareness and 
decrease associated barriers to prescribing MC for patients with qualifying conditions? 
The clinical question guided the formulation of objectives for this scholarly project. 
Objectives 
The objectives of this scholarly project are to: 
1.     explore the efficacy of MC for patients with qualifying conditions. 
2.     identify knowledge gaps and perceived barriers HCP have regarding MC. 
3.     provide an educational session for HCP regarding the efficacy and perceived 
barriers to MC for qualifying conditions. 
These objectives will be met through the scholarly processes of this project. 
Patient Population and Healthcare Setting for Implementation of Project 
HCP who have a working relationship with patients who have qualifying 
conditions for Minnesota's MC program are the target population for this project.  The 
setting of the project is an educational session targeted for HCP and future nurse 
practitioners in southern Minnesota or Wisconsin. 
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Significance of Project 
MC as an accepted treatment modality is still a contested renaissance in the 
biomedical community, partly due to the many stigmas regarding MC and mixed 
legislation regarding the legality of MC at state and federal levels.  However, several 
pharmaceutical drugs derived from synthetic cannabis are available to the masses to treat 
a variety of health conditions, often featuring adverse side effects.  As acceptance in the 
medical community occurs, providers will need to acknowledge the significance and 
efficacy of MC as a treatment option. 
Because HCP certify patients, they determine patients’ access to MC.  As Lough 
(2015) portrayed, physicians are the gatekeepers of patient access to MC, and if the 
physicians remain uneducated, the gate remains closed.  For the gate to open, HCP need 
education regarding the efficacy, knowledge gaps and barriers of MC.   
Essentials and Competencies 
The objective of this scholarly project is to explore the efficacy of MC for 
qualifying patients, to identify knowledge gaps and perceived barriers HCP have 
regarding MC, and provide an educational session for HCP regarding the efficacy and 
perceived barriers to MC.  These objectives facilitate and support The Essentials of 
Doctoral Education for Advanced Nursing Practice (DONPE) and National Organization 
of Nurse Practitioner Faculties (NONPF) required by Augsburg University in fulfillment 
of the scholarly project.  The DONPE essentials and NONPF competencies are based on 
the Doctorate Nurse Practitioner-Family Nurse Practitioner programs’ professional 
objectives to fulfill and prepare students to practice across care settings in various nursing 
leadership roles. 
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In support of Augsburg’s requirements, the author has selected the most pertinent 
essentials and competencies related to this scholarly project.  This project supports 
DONPE Essential I, “Scientific underpinnings for practice” and Essential VI, “Inter-
professional collaboration amongst HCP to improve patient and population health” of the 
Essentials of Doctorate Education for Advanced Nursing Practice (AACN, 2006).  A full 
list of the Essentials of Doctoral Education is found in Appendix A.  In addition to 
meeting DONPE essentials this project fulfills NONPF competencies in the leadership 
and practice subcategories. 
This scholarly project emphasizes two NONPF competencies in the subcategories 
of leadership and practice.  The two NONPF leadership competencies are, Competency I, 
“assumes complex and advanced leadership roles to initiate and guide change” and 
Competency VI, “communicates practice knowledge effectively both orally and in 
writing” (NONPF, 2011).  Lastly, NONPF practice Competency I, “provides leadership 
in the translation of new knowledge into practice” (2011).  An expansion of these 
requirements concerning the scholarly project will be described in chapter 5. 
 This chapter serves as a foundation for this scholarly project by identifying the 
problem statement, the purpose of the scholarly project, clinical question, professional 
objectives, significance of the project, and an introduction to the doctoral essentials and 
competencies. Chapter Two will provide a literature review showcasing the non-medical 
history of medical cannabis, the efficacy of MC, barriers of MC and theoretical support 
on qualifying patients for MC. 
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Chapter Two: Literature Review 
A resurgence of MC for the treatment of a variety of symptoms and disease processes 
brings renewed hope for qualified patients in states with approved MC legislation.  
However, as providers begin to navigate a health care system that refutes the claims of 
the efficacy of MC, many barriers continue to exist for patients seeking MC and HCP 
wanting to qualify patients for MC.  Despite MC’s non-medical stance for the last half-
century, current research addresses the efficacy of MC as well as the barriers to 
qualifying patients for MC, both indicating the importance of the project’s plan for an 
educational session within Margaret Newman’s theory, Health as Expanding 
Consciousness. 
Non-Medical History of Medical Cannabis 
 For millennia, Cannabis sativa was known for its healing modalities for a variety 
of ailments.  A popular medical reference book, Pharmacopeia, featured Cannabis sativa 
for its medical uses from 1850-1942.  Negative connotation regarding cannabis began in 
the 1930s when it was suspected to make men of color become violent and solicit sex 
from white women (Burnett & Reiman 2014).  Mainstream media furthered the stigma 
and fear regarding cannabis by releasing a film, “Reefer Madness,” and by the end of 
1936, all 48 states had laws regulating cannabis. Furthermore, The Marihuana Tax Act of 
1937, required the registration and tax for all growers, sellers, and buyers of cannabis.  
Hence, society continued to fear cannabis; however, the American Medical Association 
(AMA), stood against the Marihuana Tax Act to the Committee on Ways and Means, 
because of its well-known medicinal value. (Konieczny, 2018, p. 28).  Despite efforts 
from the AMA to keep cannabis legal for its medicinal uses, fear and stigma overtook 
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their efforts, and a paradigm shift occurred.  This shift inaccurately changed the image of 
cannabis from having valued medicinal properties to that of a street drug, which further 
stigmatized the plant in the mid-twentieth century. 
 Legislation against Cannabis continued in 1970 under the Controlled Substances 
Act of 1970.  This new act unveiled a five-tier schedule of all narcotic and psychotropic 
drugs. The top tier, Schedule 1, features Cannabis, thus, claiming the highest potential for 
abuse, no medicinal value, and a lack of safety for use under medical supervision (Drug 
Enforcement Agency, 2017b). Shortly after that, Nixon’s “war on drugs” began an all-out 
offensive on drugs criminalizing marijuana use (Konieczny, 2018, p. 31).  An attempt by 
the National Commission on Marihuana and Drug Abuse to declassify marijuana as a 
“’low-priority drug’ that it was not addictive, and it did not lead to harder narcotics” was 
attempted in 1975, but ignored furthering the stigma and criminalization of Cannabis 
(2018, p. 33). The recommendation from the Commission was ignored by President 
Nixon, consequently there was limited research or scientific advancements from the 
1970s through the early 1990s. However, since the discovery of the cannabinoid receptor 
system in 1990 and the use of Cannabis for medical reasons in California in 1992 created 
a new perspective on Cannabis (Medical Marijuana, 2017). 
 Today’s perception of cannabis has shifted from an anti-stance to pro-stance.  As 
Brooks, Gundersen, Flynn, Brooks-Russell, and Bull (2017) explained, ten years ago, 
approximately one-third of the population supported legalizing cannabis, today nearly 
three-fifths of people approve of legalization.  This shift in perception may be due to the 
current integration and normalization of cannabis throughout the nation as states select to 
legalize cannabis either medicinally or for medicinal and recreational purposes. 
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 As the nation changes its perspective of cannabis and its uses, it is up to state 
legislators to determine the approval of medical cannabis for their state.  Currently, 33 
states have legalized medical marijuana for medicinal use for patients with qualifying 
conditions (Berke & Gould, 2018).  Currently, Minnesota approves of MC for qualifying 
conditions: treatment of cancer-associated pain, nausea, or severe vomiting, cachexia or 
severe wasting; glaucoma; HIV/AIDS; Tourette syndrome; amyotrophic lateral sclerosis; 
seizures characteristic of epilepsy; severe and persistent muscle spasms, indicative of 
multiple sclerosis; inflammatory bowel disease; terminal illness; intractable pain; and 
post-traumatic stress disorder (Minnesota Department of Health, 2017).  What signifies a 
qualifying condition is that it is chronic and debilitating.  When HCP have reached a 
consensus that traditional treatment measures are ineffective, there are no further 
treatment options, and the benefits outweigh the risks.  The quantification of the impact 
MC has on these conditions can only be further investigated with the approval of more 
research. 
 Until further examination of MC is permitted, a knowledge deficit regarding the 
efficacy of MC exists for patients and providers alike.  The DEA Resource Guide on 
Drugs of Abuse, explains that both the DEA and the Food and Drug Administration 
(FDA), must provide the federal authority to approve marijuana for medical use (DEA, 
2017a).  These two federal agencies are the gatekeepers of the deregulation and sanction 
of cannabis for medicinal purposes; the FDA does approve synthetic marijuana by the 
brand names of Marinol, Syndros, and Cesamet (Porter, 2017).  Legalizing MC on a 
federal level would provide opportunities to investigate and evaluate the efficacy and 
safety of MC for different conditions as well as provide a framework for policies and 
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protocols to standardize the use of MC.  To further understand the implications and 
effectiveness of MC, it is imperative to have background knowledge about the plant 
composition and function, which is the endocannabinoid system. 
Efficacy of Medical Cannabis 
Physical Effects 
 The discovery of the endocannabinoid system (ECS) is profound because the ECS 
regulates many physiological responses.  The ECS is found throughout the body, 
comprised of phytocannabinoids.  While there are hundreds of phytocannabinoids, the 
two researched phytocannabinoids are cannabidiol and 9-Tetrahydrocannabinol (THC).  
Primarily, molecules like tetrahydrocannabinol activate and pair with the ECS receptors, 
CB1 and CB2. 
 The CB1 receptor is a non-competitive antagonist with cannabinoids.  CB1 is the 
primary cannabinoid of the central nervous system.  Additionally, CB1 is ten times more 
common in the brain than opioid receptors (McGenney, 2013).  The lack of CB1 
receptors on the brain stem and the cardiopulmonary centers allows a patient to take MC 
for pain without respiratory depression.  This insight is a significant finding, mainly 
because of the current opioid epidemic. 
 The receptor CB2, similar to CB1, is found in the central nervous system but is 
mostly affiliated with the immune system and peripheral nervous system.  Due to the 
concentration of CB2 in the immune system, it is theorized to play an important role and 
function of inflammatory processes (McGenney, 2013).  This finding promotes further 
investigation on how CB2 plays a role in signaling pain and inflammatory pathways. 
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 Furthermore, the United States government has a patent on cannabinoids as 
antioxidants and neuroprotectants.  This license is related to the treatment of 
neurodegenerative diseases such as “Alzheimer’s disease, Parkinson’s disease, and HIV 
dementia” and its protectant role “following ischemic insults, such as stroke and trauma” 
(Hampson, Axelrod, & Maurizio, 2003, para. 1).  The ability of the ECS to influence 
various effects on the body has resulted in a renewed interest in MC and its efficacy on 
several disease states and conditions.  The ECS and its’ multiple components make it a 
prime focus for new research to evolve with the implications affecting different diseases 
and disorders. 
Chronic Pain and Medical Cannabis 
 Chronic pain (CP) is the most common reason people seek MC; therefore, the 
efficacy and findings relating to MC and CP management are more significant than ever.  
Whiting, Wolff, and Deshpande (2015) reported that moderate-quality evidence exists for 
cannabinoids to treat CP.  These findings, in the current opioid epidemic (OE), highlight 
the importance of furthering research in the area of MC and pain management. 
 The necessity of more research stems from the point that the OE has reached 
epidemic proportions, afflicting every cohort of society; an estimated 64,000 people 
overdosed in 2016 from opiates (Hirschfield, 2017).  On October 26th, 2017, President 
Donald Trump declared a “national health emergency” on the OE but did not request any 
additional funds to address the issue; his recommendation was to incorporate a “just say 
no” approach.  Current initiatives include decreasing prescription rates, sharing data and 
effective strategies with key stakeholders, identifying risk factors, and increasing 
awareness and knowledge within the community about opioids (Centers for Disease 
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Control, 2017).  A standardized approach to managing CP with MC would create positive 
outcomes for patients. 
 There is growing evidence of positive outcomes of incorporating MC into a 
treatment plan for someone that has CP.  By substituting opioids with MC, the harm 
potential reduces, and a person’s quality of life increases while decreasing the morbidity 
and mortality rates (Lucas, 2017).  States with approved MC use have a 24.8% lower 
annual opioid overdose mortality rate than states without MC laws (Bachhuber, Saloner, 
Cunningham, & Barry, 2014).  Additionally, states with MC legislation found that per 
physician, opioid prescriptions decreased by 1826 annually; furthermore, introducing MC 
before opioid therapy effectively interrupts the cycle of opioid use, as well as an adjunct 
treatment to methadone to increase treatment success rates (2017).  These outcomes 
correlate the optimistic effect that MC has on CP and illuminates the positive outcomes 
MC can have on other disease states as well. 
Substitution of Pharmaceuticals with Medical Cannabis 
 Current literature indicates a promising treatment option to substitute, augment, or 
titrate-down opioid use with MC.  Boehnke, Litinas, and Clauw (2016) found that of 244 
MC patients with CP, those who used MC experienced a “64% decrease in opioid use, 
decreased number and side effects of medication, and a 45% improvement on [their] 
quality of life” (p. 739).  This survey pointed out that CP plays a significant role in 
patients’ everyday life and that integrating MC may do more than decrease pain by 
eliciting a more comprehensive approach to the pain experience.  Furthermore, Feingold, 
Brill, Goor-Aryeh, Delayahu, and Lev-Ran (2017) found that CP patients experience 
higher levels of anxiety and depression, receiving prescription opioids than those 
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receiving MC.  This finding supports that MC assists in alleviating levels of anxiety and 
depression, which reflects the wide-ranging effects of the ECS. 
 People are substituting opioids, benzodiazepines, and antidepressants with MC.  
Corroon, Mischley, and Sexton (2017) found that of 2,774 individuals, “1,248 (46%) 
respondents reported using cannabis as a substitute for prescription drugs” and the most 
common classes of drugs substituted were “narcotics/opioids (35.8%), 
anxiolytics/benzodiazepines (13.6%) and antidepressants (12.7%)” (p. 989).  Similarly, 
Lucas and Walsh (2017) surveyed authorized MC patients to examine the substitution 
effect; the authors found a “high self-reported use of cannabis as a substitute for 
prescription drugs (63%), particularly pharmaceutical opioids (30%), benzodiazepines 
(16%), and antidepressants (12%)” (p. 30).  These studies indicate that patients are 
substituting MC for highly addictive, highly scheduled medications; thus, patients are 
reducing the harm potential of pharmaceutical agents. 
 As patients continue to substitute or titrate-down FDA approved opioids, 
benzodiazepines, and antidepressants with MC, HCP need to be aware of the implications 
this may have on their patients’ health, potential clinical outcomes, and disease processes.  
HCP need to stay informed on current research implications to recommend all treatment 
options for their patients.  In addition to the efficacy of MC, providers need to be aware 
of current laws and regulations at a federal and state level, steps of informed consent, as 
well as knowledge regarding patient and provider barriers. 
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Barriers of MC 
Patient Barriers 
 The current status of MC in the US is difficult to navigate.  Many states do not 
have the same qualifying conditions, require different processes for becoming registered, 
and have various allowances and guidelines for obtaining MC.  Therefore, patients in 
different states may not be aware or informed of the MC laws in their state.  Until MC is 
federally legal, the landscape of MC will remain a patchwork of different state laws and 
regulations.  Minnesota was the 22nd state to pass legislation for MC, beginning its use 
for qualifying patients. 
 The office of MC in Minnesota was initiated in May 2014 to guide new MC 
legislation.  According to the Minnesota Department of Health (2017), the current 
registration process begins when a patient has a qualifying condition; then, the provider 
approves the condition by certifying the patient online in the registry.  Next, the patient 
visits a patient cannabis center located throughout Minnesota in Hibbing, Moorhead, St. 
Cloud, Minneapolis, St. Paul, Bloomington, Eagan, and Rochester.  Once at the registry, 
the patient must provide a valid ID and proof of payment and receives a consultation 
from the dispensary pharmacist and staff.  The patient may then select which form of 
cannabis to choose from pill, liquid, or oil; Minnesota is the only state program that does 
not allow the route of inhalation or plants (2017).  The MC used in Minnesota is 
authorized, regulated, and inspected.  Information regarding the MC program in the state 
of Minnesota is accessible at health.state.mn.us.  These necessary components provide a 
safe and efficacious way of integrating MC into practice in Minnesota. 
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 Since Minnesota’s inception of MC, the Minnesota Department of Health has 
instituted a comprehensive analysis of the patient’s perspective of using MC.  A review 
of patients and HCP from July-September 2015 found that 88% perceived to benefit from 
MC (Minnesota Department of Health, 2016).  The highest reported positive benefits 
among patients and HCP were “improved quality of life, sleep, mobility, cognitive 
functioning or reduced anxiety” (Minnesota Department of Health, 2016, p.79).  The 
most common patient-reported adverse effects of MC included “dry mouth, seem to be 
more tired, cost, and distance” (Minnesota Department of Health, 2016, p.79).  
Additionally, patients viewed adverse effects as the “stigma of MC” and “new neighbors 
felt that it was not right for anyone to use MC” (Minnesota Department of Health, 2016, 
p.79).  One patient reported that, “care providers (other than my registered provider) are 
apprehensive to participate in the program” and that a “lack of education, widespread 
communication in the medical community regarding the benefits and laws regarding 
MC” (Minnesota Department of Health, 2016, p. 80).  This brief summation of patients’ 
and HCP’ reports of their experiences of MC indicates that the positive benefits outweigh 
the negative.  According to these patients, adverse opinions of MC center on stigma, cost, 
and distance to the dispensaries.  Furthermore, patients have reported providers feeling 
the stigma as well, indicating the critical need for HCP education regarding MC 
(Minnesota Department of Health, 2016, p. 80).  These patient testimonials provide 
insight into the benefits and stigmas related to MC, and they provide awareness about 
associated barriers between the patient and HCP’. 
Provider Barriers 
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 Currently, there are few to no provider education programs on MC.  A majority of 
providers obtain their knowledge of MC from non-peer reviewed sources such as social 
media, news, and other providers (Carlini, Garrett, & Carter, 2017).  These sources are 
inadequate for HCP to make an informed decision regarding MC for their patients and a 
failure to patients who want more information on MC for their qualifying condition(s).  
What HCP desire, according to a survey of 494 HCP in Washington state, is training that 
would include the use of clinical algorithms, dosing guidelines, and best clinical practices 
(Carlini et al., 2017).  Education for HCP regarding MC should focus on qualifying 
conditions per their state, the difference effects via different routes, different dosage 
strengths, and drug interactions of MC with pharmaceutical agents.  Furthermore, 
differences in gender, age, and mental health concerns should also be factored in and 
addressed when qualifying a patient.  A questionnaire developed by Carlini et al. (2017) 
found providers comfort level with MC would increase if there were “education programs 
for healthcare providers, more clinical data, more research proving effectiveness, 
algorithms for recommending MC, endorsed clinical guidelines, and change in cannabis 
federal legal status” ( p. 87).  However, without peer-reviewed research, it is very 
challenging to develop a standardized educational program, thus the need to de-schedule 
MC to make it available for research purposes. 
Theoretical Support on Qualifying Patients for MC 
 Current suggestions for providers include having candid, open conversations with 
patients about cannabis use and the effects it may have on their overall health and 
medical condition.  Subsequently, to enhance conversations between patients and HCP, 
techniques such as motivational interviewing, providing informed consent through 
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evidence-based research, and increasing care access, remain top priorities for providing 
quality patient care (Lenoue et al., 2016).  These skills are beneficial in building rapport 
and transparency for the patient and HCP throughout the consent process. 
 The consent process begins when the patient has “failed” standard treatment 
regimens, and the HCP believes the patient will benefit from MC.  Additionally, the 
registered HCP understands the therapeutic science of MC and can make an informed 
decision on behalf of the patient.  The steps of informed consent are as follows: 
1. Volunteerism, meaning the HCP are “cognizant of this concept as 
preexisting bias will confound the process, adding elements of undue 
persuasion” (Leoue, Wongnmnit, & Thurston, 2016, p. 475) This process 
allows for the patient to make a rational choice on the decision to pursue 
MC.  
2. Competency, thus, understanding the necessity, risks, and potential 
benefits of the intervention of MC. 
3. Provision of information, providing the most up to date literature 
regarding MC and possible side effects, potential drug interactions, and 
alternatives to MC. 
4. Understanding, all of the possible positive and negative outcomes of 
using MC. 
5. Informed consent and an expression of the patient’s decision is reached 
once the patient expresses a clear understanding of MC and the 
consequences of using MC (Lenoue et al., 2016). 
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 These guidelines of the consent process for MC are a helpful tool for HCP; to 
assist them to competently manage their patients. 
 HCP are the gatekeepers of MC; HCP’ acknowledgment of the non-medical 
history, efficacy, barriers, and theoretical support of MC influences their patients access 
to MC.  Furthermore, it is HCP’ role to educate, safely incorporate, and follow up with 
their patients regarding MC and their treatment regimen. Chapter Three will focus on 
Margaret Newman’s theory, Health as Expanding Consciousness, which will guide this 
scholarly project.   
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Chapter Three: Application of Theory 
The goal of this scholarly project is to identify knowledge gaps regarding MC and 
provide education to HCP in southern Minnesota regarding the significance, efficacy, and 
resources available, to incorporate MC into their practice.  This scholarly project is 
significant because many HCP may be unaware of the implications, effectiveness, and 
resources correlated with MC.  As a result, patients will not receive MC as a treatment 
option for their qualifying conditions.  This chapter will summarize this scholarly project, 
describe Margaret Newman’s Theory of Health as Expanding Consciousness, and explore 
its relation to this scholarly project. 
Summation of Scholarly Project 
To provide HCP with knowledge and information regarding MC to better serve 
patients who, inquire about using MC for their qualifying condition(s), barriers must be 
addressed.  Currently, there are several barriers for patients, including the stigma 
associated with a patient’s use of MC for a qualifying condition, HCP’ lack of resources 
and knowledge on how to certify a patient to use MC, and the debated efficacy of using 
MC for qualifying conditions.  The goal of this scholarly project is to educate a cohort of 
HCP to serve their patient population better, whether by providing resources to their 
patients’ or referring their patients to HCP who can certify their patient.  Successful 
implementation of this project will include an educational session for HCP to serve their 
patient population better in southern Minnesota through, dialogue and discussion about 
MC.  Additional education will assist HCP to identify the efficacy and perceived barriers 
to MC for patients with qualifying conditions.   
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Margaret Newman’s Theory of Health as Expanding Consciousness 
 Margaret Newman’s Theory of Health as Expanding Consciousness translates 
chaos into a new pattern of thinking, thus expanding one’s consciousness about health.  
Newman’s (1979) Theory of Health as Expanding Consciousness foundation is on the 
premise of a positive relationship influencing another’s energy pattern, ultimately leading 
to a change in one’s pattern and expanding one’s consciousness.  These fluctuations in 
energy and repatterning occur between the patient and HCP and parallel the interaction of 
presenter and audience.  As energy is shared between the presenter and the audience, new 
patterns emerge out of the relationship, which creates changes in one’s consciousness. 
 The premise of Newman’s (1979) theory is that a relationship based on mutuality 
for the patient creates a shift in their pattern of thoughts, thus creating a higher level of 
consciousness.  In Newman’s theory, the nature of the pattern is portrayed as information.  
This information depicts the whole, understanding the meaning of all information at once.  
The context of a pattern is with a person at all times, but it shifts and changes as a person 
experiences life; it is self-organizing, diverse, rhythmic, and continuously in motion 
(Newman, 1994).  These patterns are not separate and are part of the components of the 
fluctuating, expanding universe.  Pattern visualization is conceptualized when the viewer 
takes a look at the pattern from a broader context, which allows the individual to 
comprehend the whole; therefore, pattern visualization allows for understanding of 
longstanding paradigms of care.  Whereas, a shift in consciousness represents a new 
pattern of care. 
 New patterns are part of the process of creating changes in consciousness.  These 
new patterns are described as information of the system, the capacity of the environment 
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to interact with the system (Newman,1994).  These events occur when a rhythmic pattern, 
becomes interrupted by a new critical element or chance event, which brings fluctuation 
to the pattern.  Newman’s (1979) theory is that this variation causes changes to the 
pattern to become disorganized from which a new pattern of organization will occur.  
This new pattern or rhythm occurs with an input of energy from the environment.  
According to Newman, until a new higher-level pattern emerges, there are moments of 
uncertainty, which is a critical element of this theory.  Ambiguity is a time for the person 
to make a transition, to change, to develop a new pattern of thought from one perspective 
to a higher-level perspective.  Therefore, a disruption in a pattern to a newly organized 
system of thought and consciousness creates a new set of ‘rules’ or ‘orders’ that direct 
thought processes (Newman, 1994).  As a person changes these old patterns to new 
thought processes changes, occur in their consciousness.  
 These new thought processes stem from a turning point when the old ways 
(patterns) no longer work.  Thus, to advance change, a new, awakened awareness of 
current habits is evaluated to transcend to new thought processes.  This new 
understanding is possible by creating a partnership.  The act of partnering elicits a mutual 
relationship, trusting that at the end of the process, a new, higher consciousness will 
unfold (Newman, 1994).  The goal of this paradigm shift is to transition focus beyond 
self and incorporate the perspectives of the universe. 
Integration: Scholarly Project and Theory 
 Newman’s (1979) Theory of Health as Expanding Consciousness supports the use 
of partnership between two parties to recognize a disturbance or chaos in the current 
pattern to create a new pattern that promotes a higher level of consciousness.  In this 
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scholarly project, the notion of pattern portrays the current state of nurse practitioners 
providing care to their patients who may qualify for MC, which parallels the process of 
educator and audience.  Therefore, the existing old paradigm works until a critical event 
influences a change in the rhythm of the pattern creating a different perspective on the 
current issue. For example, the premise of a patient inquiring about MC for care is the 
critical event, thus, creating a ripple effect in the energy patterns of the patient and HCP 
and an expanding of consciousness.   
 Achieving a higher level of consciousness, a new pattern of thought, a partnership 
is necessary to evolve the chaos into a new pattern.  During an educational session, a 
‘meeting’ takes place between consciousness and different patterns of thought, requiring 
a shared consciousness.  By integrating these different energy patterns, a new pattern 
emerges, which creates a higher consciousness of thought.  Lastly, after interacting and 
broadening the horizon of one’s consciousness, the meeting dissipates, and the energy 
patterns move apart to different perspectives, but not without being influenced by one 
another’s energy field.  Due to the complexity of the process of two separate energetic 
thought patterns influencing one another to create a higher level of consciousness, a 
concept model best illustrates the dynamic interplay.   
 A concept model illustrates the notion of partnership between presenter and 
audience.  As Falkenstern, Gudeldner, and Newman (2009) confirmed, a partnership can 
facilitate change and action by giving time and space, allowing freedom of expression, 
considering choices, and creating empowerment by using a model of health as expanding 
consciousness.  Additionally, in a literature review, Younas and Parveen (2017) found 
support for Newman’s Theory by summarizing that Newman’s theory on the premise that 
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“expanding consciousness is the result of meaningful interactions of people with their 
environment” (p. 209).  Based on these assumptions of interaction and expanding 
consciousness, the conceptual model in Figure 3.1 shows this portrayal via a simple 
diagram.  The presenter and audience share and interact with their energies, which is 
represented by the plus symbol, illustrating the interplay of energies.  The arrow 
represents the patterning and assimilation of thoughts, finally manifesting as an 
expansion of consciousness between the two subjects.   
Figure 3.1: Theoretical Model of Expansion of Consciousness 
 
 While this conceptual model provides a simplified version of the dynamic 
exchange between the two energy fields, it portrays that as two subjects come together 
and exchange energies, a newly created expansion of consciousness results.  The 
resulting expansion of consciousness between presenter and audience involves an 
interaction of two energy fields, repatterning, and an expansion of consciousness 
resulting from the dynamic interplay.  The interactions aim to expand one’s 
Presenter 
Audience
Expansion of 
Consciousness
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consciousness allowing the formation of new thoughts and, subsequently, new patterns of 
health and healing.   
 Newman’s (1979) Theory of Health as Expanding Consciousness explains the 
dynamic interaction between two energy fields as they interplay to create new patterns 
and expand one another’s consciousness, thus creating new patterns of health and 
healing.  These significant interactions theorize the interplay of presenter and audience 
and the expansion of consciousness that occurs during a presentation.  Chapter Four 
expands on the methodology and evaluation of a PowerPoint presentation to HCP 
regarding MC, specifically CBD. 
 
  
MENTAL HEALTH AWARENESS  23 
Chapter Four: Methodology and Evaluation 
 A palliative nurse practitioner care team from northwest Wisconsin requested 
more information regarding CBD, the non-psychoactive part of cannabis that acts as an 
anti-inflammatory, antioxidant, and neuroprotectant, specifically, CBD derived from 
hemp, which is federally legal.  The palliative nurse practitioner cares for patients who 
have chronic, debilitating conditions or are transitioning to hospice care.  Also, this 
patient population may experience chronic pain and neuralgias, while experiencing 
adverse side effects from pharmaceuticals; thus, motivating them to substitute their 
pharmaceuticals with medical cannabis and CBD to manage their symptoms and improve 
their quality of life (Boehnke et al., 2016; Corroon et al., 2017).  As the palliative nurse 
practitioner care team acknowledged their patients’ inquiries about CBD, they too began 
asking questions about CBD, specifically, the efficacy, legality, and how to incorporate 
CBD into their patients’ care regimen.  As part of the scholarly process, this author 
presented to the palliative nurse practitioner care team concerning their particular 
objectives (see Data Collection), via a PowerPoint presentation, which lead to in-depth, 
thought-provoking discussions about hemp-derived CBD and broader conversations 
about medical cannabis for their patient population. 
Subjects 
 The primary subject group included a palliative nurse practitioner group of six 
individuals; also, in attendance were two registered nurses and one certified medical 
assistant.  This care team’s patient population have complex, often terminal medical 
diagnoses or disease states that require integrative symptom management from multiple 
modalities. 
MENTAL HEALTH AWARENESS  24 
Clinical Setting 
 The primary care setting was a community hospital in a small town in northwest 
Wisconsin.  Initially, the clinical setting for this scholarly project was to be in southeast 
Minnesota.  However, due to the outreach from the palliative nurse practitioner group in 
Wisconsin, their clinical setting became the primary focus of this scholarly project.  
Implementation of the scholarly project was held in a meeting room that provided space 
for a PowerPoint presentation and roundtable discussions.   
Intervention 
 Before the implementation of this presentation, the palliative nurse practitioner 
care team outlined their objective via email.  The process of sharing this information via 
PowerPoint, followed by an open discussion, served as the developmental evaluation for 
this scholarly project.  Per Patton (2011) developmental evaluation “supports innovation 
development to guide adaptation to emergent and dynamic realities in complex 
environments” (p. 1).  In this scholarly project the developmental evaluation process was 
exploring the innovative subject CBD and associated objectives (see Data Collection), 
comments, and concerns of incorporating CBD into a patient’s treatment plan.   
Data Collection 
 The palliative nurse practitioner care team sent objectives to the presenter as 
discussion points on the following topics:  
what is medical cannabis, specifically CBD,  
is there research on its efficacy, 
 is it legal in all states, 
how would providers order it,  
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would it show up on a drug test, and  
in what forms is CBD available?   
These objectives were the main points of the PowerPoint presentation (see Appendix C) 
and were also important discussion topics following the presentation. 
 Following the presentation and discussion, a survey (see Appendix D) was 
distributed to all attendees to evaluate if objectives were met.  Eight of the nine 
participants were able to complete the survey, because one person had to leave to assist a 
patient; the survey as a follow-up process allows for further analysis of discussion points 
and improvements of the presentation process. 
Results and Analysis 
 The analysis of the survey results of seven Likert Scale questions ranging from 
strongly disagree to strongly agree, including two open-ended questions were asked on 
the survey. Overall, the participants agreed or strongly agreed to questions #1-#4 (see 
Appendix D) that the content was informative to their practice.  Participants had a greater 
understanding of CBD, awareness of the physiology of CBD, the efficacy of CBD, and 
knowledge of the resources available about CBD. 
 The questions, “I am more comfortable, speaking and informing my patients 
about CBD,” and “In the future, I will recommend CBD to my patients,” did not pertain 
to three participants because they are not primary care nurse practitioners.  The 
participants’, role was considered while reviewing survey results.  The solo follow-up 
question from the survey results was, “How to know where the best places to purchase 
[CBD] from?” This question was discussed via round table discussion following the 
presentation but requires further follow-up due to the multitude of factors that create a 
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reputable source when obtaining CBD.  Additional discussion themes included how to 
recommend CBD to their patients, how to incorporate a recommendation in a provider 
note, and dosage strengths for their patient population.  All of the participants were 
engaged and had a critical, thoughtful dialogue about CBD, as well as found the topic 
essential and pertinent to providing holistic patient care. 
 The conversation topics of medical cannabis, explicitly incorporating CBD into 
patient care, will need to be discussed in ongoing conversations throughout medical 
paradigms as patients become more aware of the efficacy that has on disease processes.  
It was evident that these groundwork conversations about incorporating medical cannabis 
into patient care invigorated the palliative care team.  
Furthermore, it was evident that these conversations will continue to take place as health 
care consumers demand alternative approaches to pharmaceuticals for health and 
wellness.   
 A palliative nurse practitioner care team in northwest Wisconsin acknowledged 
and listened to their patient requests about CBD.  The patients were curious if CBD could 
augment their current treatment plans and improve their symptoms associated with their 
disease states.  As a result of the patients’ requests, the author was contacted from the 
Integrative Medicine Division at Mayo Clinic, and an informative session was held 
discussing the care teams’ stated objectives.  As part of the developmental evaluation 
process, a presentation and open discussion was held, and a post-presentation survey was 
given to participants to evaluate the PowerPoint intervention.  The content of Chapter 
Five will focus on Augsburg University’s program essentials and competencies 
concerning this scholarly project, critical reflection on the project, advancement in 
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nursing practice, gaps in the literature that this project addresses, as well as future ideas 
and suggestions for future project implementation.   
  
MENTAL HEALTH AWARENESS  28 
Chapter 5: Conclusions, Significance, and Implications for Future 
 Different states have different laws regarding people’s ability to qualify and 
receive MC.  Currently, Wisconsin has one minimal MC law.  This law, 2017, Wisconsin 
Act 4, states that only patients with a seizure disorder may get certified for MC, and even 
then, qualified patients may only have CBD, the non-psychoactive form of MC and 
primary cannabinoid of hemp.  Furthermore, there is not a dispensary that provides CBD 
to these patients.  A solution for patients wanting CBD is to obtain CBD from hemp, 
which is federally legal.  Consequently, the patient’s want more information about CBD 
and its medicinal uses, so they ask their HCP.   
 A group of palliative and hospice health care providers, primarily nurse 
practitioners, requested more information regarding CBD for their specialty patient 
population.  This request presented an opportunity for the author to implement the 
following objectives the team suggested, to review during the implementation phase of 
the scholarly project: define CBD, its efficacy, its legality, prescribing, drug testing, and 
forms and absorption of CBD.  This chapter will examine how this scholarly project 
exemplifies the Doctor of Nursing Program Essentials (DONPE) and the National 
Organization of Nurse Practitioner Faculties (NONPF) Competencies as well as 
conclusions, significance to practice, and implications for future work as revealed by this 
project.  
Doctorate of Nursing Program Essentials 
 In accordance with Augsburg University’s Department of Nursing’s requirement, 
applicable DONPE was implemented in this scholarly project.  The basis of this scholarly 
project is DONPE I, “scientific underpinnings for practice” (AACN, 2006).  This 
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scholarly project addressed the efficacy and physiology of CBD and translated that into 
content and terms, the palliative nurse practitioner care team could implement into 
practice.  The process of implementing evidence-based content into practice is the 
foundation for improving patient outcomes and quality of life. 
 As HCP explore and examine ways to improve patient’s quality of life and patient 
care, it is critical to reach out to content experts.  Inter-professional collaboration between 
health care teams elicits DONPE VI, “Interprofessional collaboration for improving 
patient and population health” (AACN, 2006) (see Appendix A for all eight essentials).  
The palliative care team inquiring about medical cannabis, specifically CBD, was a 
pivotal moment for the author because it surfaced the importance of inter-professional 
collaboration to improve patient care by exploring the efficacy of CBD to improve 
patient symptoms in the palliative nurse practitioner specialty group. 
National Organization of Nurse Practitioner Faculties Competencies 
 This scholarly project aimed to provide education to HCP, specifically nurse 
practitioners regarding CBD.  This developmental process required multiple steps of 
reaching out, contacting, and identifying objectives the palliative care team specified as 
well as providing the education to initiate and guide change.  This project meets the first 
NONPF leadership objective, “assumes complex and advanced leadership roles to initiate 
and guide change” (NONPF, 2011) (see Appendix B for a complete list of competencies).  
The primary delivery of content was a PowerPoint mixed with open dialogue for 
comments, concerns, and questions.   
 After the presentation, the hospice care team and the author spent time discussing 
the positive and negative aspects of incorporating CBD into their practice.  For example, 
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the HCP expressed concerns about the legality of recommending CBD to a patient and 
how to document in the patient’s chart if the patient decided to take CBD.  In retrospect, 
it is those particular types of conversations that provide the foundation of guiding 
practice change. 
 A second leadership NONPF competency this scholarly project met was 
Competency VI, “communicates practice knowledge effectively both orally and in 
writing” (2011).  The presentation lifted objectives the care team had identified, therefore 
identifying and addressing knowledge gaps.  This presentation included three mediums of 
content delivery: including a PowerPoint presentation, a print out of the PowerPoint 
slides so the audience could follow along and take notes, and informative, interactive 
dialogue regarding questions, comments, and concerns of implementing CBD into 
practice. 
 Currently, CBD and MC are in the pioneer stages of incorporating knowledge into 
practice.  Essentially, there is a vast amount of research needed to understand CBD 
better; specifically, CBD and MC’s role in patient care.  Due to the legality of MC, many 
research opportunities are terminated; therefore, there is a lack of knowledge about MC 
and CBD.  However, patients continue to use the herb in a variety of settings for the 
plant’s perceived and noted medical effects.  It is imperative to acquire and share current 
evidence and knowledge into the practice setting.  This project meets NONPF practice 
Competency I, the process of “providing leadership in the translation of new knowledge 
into practice” (2011).  This competency may be the most crucial NONPF criterium this 
project met because of it of lack of knowledge regarding MC and CBD and the demand 
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from patients and consumers wanting more information to improve their symptoms and 
overall health. 
Critical Reflection on the Practice Project  
 After completing the implementation phase of the project, it was invigorating and 
insightful to bear witness to the conversations among HCP after the presentation, because 
they paralleled many of the current issues regarding the necessity and complexity of 
expanding and creating comprehension, as well as resources, regarding CBD and MC.  
This scholarly project exemplifies and addresses the questions, comments, and concerns 
many HCP have regarding a new, non-pharmaceutical treatment modality in their 
practice.  How this project advances nursing practice, gaps in the literature, insight into 
future steps for advanced nursing practice, the next steps the author will explore, and 
modifications the author would make to improve this scholarly project are the topics of 
the reflection. 
Advancement in Nursing Practice 
 In concordance with the aim of advancing nursing practice, a post-presentation 
survey was handed out to the Wisconsin palliative care team (see Figure 5.1) to assess 
their comprehension of CBD better.  The survey results indicated the following: 
 four out of eight persons surveyed felt the content regarding CBD was 
 informative to their practice; 
 seven out of eight HCP felt they had a greater understanding of CBD;  
 six persons agreed, one strongly agreed, and one replied not applicable to being 
 aware of the physiology of CBD; 
 five out of eight persons agreed about the efficacy of CBD; 
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 two strongly agreed, and 1 responded not applicable, four persons agreed and four 
 strongly agreed that they were aware of the resources available to them about 
 CBD;  
 six out of eight persons agreed that they were more comfortable speaking and 
 informing their patients about CBD; 
 while two replied not applicable and four out of eight persons did not think their 
 practice would change from their new knowledge comprehension; 
 one person agreed, one person strongly agreed that their practice would change, 
 and two people responded not applicable. 
Overall, these survey results translate to an increased understanding, awareness, and 
efficacy of CBD, increased awareness of informative resources of CBD increased 
confidence in patient education regarding CBD, and increased probability of HCP 
recommending CBD to their patients.   
 Additionally, the survey contained two-open ended questions to gauge audience 
needs, which opened further questions regarding CBD or MC are and writing any 
additional comments or questions.  The only follow-up question received was, “How to 
know where the best places are to purchase from?”  This question is very applicable 
because there are many commercial sellers of CBD and CBD-infused products.  
Therefore, as a consumer, it is essential to verify the sourcing and processing of the CBD 
before purchasing the product to ensure a high-grade quality product.   
Gaps in Literature This Project Addresses 
 Many gaps exist in the literature related to MC, such as inadequate knowledge 
and training regarding MC and CBD, little to no provider education, the complexity of 
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certifying patients, barriers to access per the patient report, and various allowances and 
guidelines for obtaining MC.  Ultimately, until MC is federally legal and de-scheduled 
from a schedule I drug, there will be few scientific advancements in the field.  Therefore, 
it is essential to continue to educate HCP about the physiology, efficacy, and current 
knowledge of MC and CBD and about how different state and federal laws impact their 
practice.  Specifically, this scholarly project addresses sharing content knowledge about 
the physiology and efficacy of CBD, as well as resources available to HCP in order to 
confidently recommend or answer patient questions regarding CBD in the 
hospice/palliative setting.   
 Recently, a pilot program in Illinois exemplified the gaps in the literature that 
HCP are experiencing throughout their practices regarding CBD and recommendations 
for their patients.  According to Temple, Lampert, and Ewigman, (2018), the barriers and 
gaps in the literature are:  
• Inadequate scientific research regarding effectiveness, dosage, delivery, mechanism, 
indications, and drug interactions;  
• Lack of educational standards and training for medical staff and dispensaries; 
• Lack of communication and coordination of patient care; 
• Complexity and inconsistent availability of dosing options; and 
• Barriers to access for patients seeking therapy (para. 1) 
This study confirmed current evidence in the literature that several topics impede 
HCP’s knowledge about MC and CBD; therefore, it is crucial to share current 
evidence-based knowledge about MC and CBD in order to advance nursing 
practice. 
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Future Implications to Advance Nursing Practice 
 Findings derived from the implementation phase of the scholarly project provides 
insight for future implications for advancing nursing practice.  The next steps should 
include continued education for HCP, incorporating scientific evidence of MC and CBD 
and thereby illuminating the significance and efficacy of MC.  Because there are limited 
resources regarding MC, the development of an informative tool or resource guide for 
HCP to certify their patients, would positively advance nursing practice. 
 Lastly, future implications should include supporting and influencing policies 
about MC at regional, state, and federal levels that de-schedule cannabis, because most 
research available is based on qualitative studies and anecdotal reports.  Therefore, until 
there is deregulation of marijuana, opportunities for increasing evidence-based 
knowledge, on a large-scale, about MC and its benefits, as well as disadvantages, will 
remain undetermined.  The process of deregulating MC begins when HCP become more 
involved at a systems level, advocating for their patients, and providing current 
information about the safety, uses, and efficacy of MC.  As legislators and policymakers 
become educated about MC, hopefully, they will revise and reverse current policies that 
halt the research on MC.  
Future Implications for Author 
 Because current policies prohibit large-scale, quantitative research studies of MC, 
it is essential to share current knowledge to a variety of healthcare settings.  The next 
steps for the author will include sharing content regarding provider education about MC 
at a local, regional, and national level.  This step will include offering to speak about MC 
at local and regional meetings to various nursing organizations as well as submitting 
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abstracts to state and national conferences.  Exposure of MC and its role in healthcare in 
various settings creates fundamental change by a grassroots effort to influence and 
advance nursing practice.   
 In Minnesota, the agency that provides MC to certified patients is Minnesota 
Medical Solutions, commonly referred to as MinnMed.  MinnMed is a physician-based 
company that provides “best in class medical cannabis products and compassionate care” 
(Vireo Health, 2018).  This company has locations throughout Minnesota for patients 
who become certified through their primary care provider for their qualifying condition.  
Additionally, this company also serves as a resource for HCP, making it a wealth of 
knowledge for the community and the author.  Therefore, the next step for the author is to 
contact MinnMed to investigate any part-time employment opportunities to expand the 
author’s understanding of MC and its functionality in patient care.   
 Currently, there are opportunities for professional membership as a registered 
nurse to belong to the American Cannabis Nurses Association.  According to the 
American Cannabis Nurses Association (n.d.), cannabis nursing is “the incorporation of 
knowledge of the endocannabinoid system and the safe use of herbal cannabis into 
standard nursing practice and the awareness of legal complexities attached to this herb” 
(para.1).  Membership in this organization, as well as becoming a certified cannabis 
nurse, creates credibility to the role registered nurse as well as to MC as a viable 
treatment modality for patients with certifiable healthcare conditions.  The mission of the 
American Cannabis Nurses Association is “to advance excellence in cannabis nursing 
practice through advocacy, collaboration, education, research, and policy development” 
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(para. 1).  Professional membership to this organization would create a wealth of 
knowledge and resources to help advance MC and its role in health care. 
 There are multiple steps for the author to explore in order to advance personal and 
professional knowledge of MC.  The aim of these different educational pathways and 
opportunities is that knowledge is shared and cultivated to better advocate for MC and its 
uses in healthcare settings.  Furthermore, by sharing knowledge about MC and 
advocating for MC, stigma and its outdated stereotypes will be lessened as well. 
 This scholarly project aimed to advance provider education about MC and 
subsequently, CBD.  The steps to complete this project included identifying a problem, 
which emerged as a lack of education among HCP about MC and its associated 
physiology, efficacy, and resources available to HCP.  A process of collaboration 
occurred, before the implementation phase, between the author and a palliative/hospice 
group, to establish objectives for an educational presentation.  The implementation phase 
involved a PowerPoint Presentation and active discussion time about MC and CBD.  This 
presentation provided an opportunity for the HCP to expand their knowledge base, 
leading to increased awareness about the role of MC and CBD.  The next step for the 
author is to explore new avenues of sharing information about MC to peers and 
associated societies, as well engage in continued education about MC and striving to 
maintain membership in the American Cannabis Nurses Association.  There are many 
avenues to explore in the sphere of MC and as patients become more aware of its benefits 
they will seek out their HCP to help them navigate this increasingly popular, yet complex 
treatment option. 
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Appendix A 
The Essentials of Doctoral Education for Advanced Nursing Practice 
The Essentials of Doctoral Education for Advanced Nursing Practice (AACN, 2006) 
 
I. Scientific Underpinnings for Practice 
II. Organizational and Systems Leadership for Quality Improvement and Systems 
 Thinking 
III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice 
IV. Information Systems/Technology and Patient Care Technology for the 
 Improvement and Transformation of Health Care 
V. Health Care Policy for Advocacy in Health Care 
VI. Interprofessional Collaboration for Improving Patient and Population Health 
 Outcomes 
VII. Clinical Prevention and Population Health for Improving the nation’s Health 
VIII. Advanced Nursing Practice 
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Appendix B 
National Organization of Nurse Practitioner Faculties 
Leadership Competencies 
1. Assumes complex and advanced leadership roles to initiate and guide change.  
2. Provides leadership to foster collaboration with multiple stakeholders (e.g. patients, 
community, integrated health care teams, and policy makers) to improve health care. 
3. Demonstrates leadership that uses critical and reflective thinking. 
4. Advocates for improved access, quality and cost-effective health care. 
5. Advances practice through the development and implementation of innovations 
incorporating principles of change. 
6. Communicates practice knowledge effectively both orally and in writing. 
7. Participates in professional organizations and activities that influence advanced 
practice nursing and/or health outcomes of a population focus. 
 
Practice Inquiry Competencies 
1. Provides leadership in the transition of new knowledge into practice. 
2. Generates knowledge from clinical practice to improve practice and patient outcomes. 
3. Applies clinical investigative skills to improve health outcomes.  
4. Leads practice inquiry, individually or in partnership with others.  
5. Disseminates evidence from inquiry to diverse audiences using multiple modalities. 
6. Analyze clinical guidelines for individualized application into practice. (NONPF, 
2014) 
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Appendix C: Survey 
Provider Education: What are Cannabinoids (CBD)? 
Augsburg University 
Morgan Rohl, RN, BSN 
rohlm@augsburg.edu or rohl.morgan@mayo.edu  
 
1.  The content regarding CBD was informative to my practice. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
2.  I have a greater understanding of CBD. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
3. I am aware of the physiology of CBD. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
4. I am aware of the efficacy of CBD. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
5.  I am aware of the resources available to me about CBD. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
6. I am more comfortable, speaking and informing my patients about CBD. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
7.  In the future, I will recommend CBD to my patients. 
 
Strongly Disagree Disagree  No Change Agree  Strongly 
Agree 
 
8. Further questions regarding CBD or Medical Cannabis are: 
 
9. Please write any additional comments or questions. 
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Figure 3.1: Theoretical Model of Expansion of Consciousness 
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Figure 5.1: Plotted Survey Results 
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Efficacy ! Research
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! Compassionate/Cannabis/Care/Act
! Medical/marijuana/is/currently/legal/in/28/states/including/the/
border/states/of/Michigan,/Minnesota,/and/Illinois./
! In/addition/to/expanding/health/care/treatment/options,/states/
that/have/legalized/the/use/of/medical/marijuana/have/experienced/
a/nearly/25/percent/drop/in/deaths/from/opioid/overdoses/
compared/to/states/that/did/not/have/those/laws.
! Bachhuber,/Saloner,/Cunningham,/and/Barry,/2014
MENTAL HEALTH AWARENESS  50 
 
Slide 7 
 
Slide 8 
 
 
 
 
Your%Role
! Recommendations
! Oral
! Sublingual
! Inhalation
! Topically
! Education
Resources
! https://echoconnection.org/education/
! https://projectcbd.org/guidance/cannabis5dosing
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! https://cannabisnurses.org
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Palliative(care(patients(experience(
chronic(pain(and(neuralgias,(while(
balancing(the(adverse(side(effects(from(
their(prescribed(pharmaceuticals,(thus,(
motivating(them(to(substitute(their(
pharmaceuticals(with(medical(cannabis(
(MC),(specifically(cannabidiol((CBD)(to(
manage(their(symptoms(and(improve(
their(quality(of(life((Boehnke et(al.,(2016;(
Corroon,(et(al.,(2017).((A(palliative(nurse(
practitioner(care(team((PNPCT)(
acknowledged(their(patients’(inquiries(
about(CBD,(they(too(began(asking(
questions(about(CBD,(specifically,(the(
efficacy,(legality,(and(how(to(incorporate(
CBD(into(their(patients’(care(regimen.(
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Subjects:(A(palliative(nurse(practitioner(
group(of(six(individuals;(also,(in(attendance(
were(two(registered(nurses(and(one(
certified(medical(assistant.(
Setting:(Community(based(hospital(in(
northwest(Wisconsin.((
Intervention:(PowerPoint(presentation(and(
roundtable(discussion(covering(the(six(listed(
objectives.
Tool:(Seven(Likert(Scale(questions(ranging(
from(strongly(disagree(to(strongly(agree,(
including(two(openSended(questions(were(
asked(on(the(survey.
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
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Many(comprehension(gaps(exist(
pertaining(to(CBD(and(MC,(such(as(
inadequate(provider(knowledge(and(
training,(barriers(to(patient(access,(
confusion(between(cannabinoids((CBD(
and(THC,)(and(the(legality(of(MC.((
This(scholarly(project(addresses(sharing(
content(knowledge(regarding the(
physiology(and(efficacy(of(CBD,(as(well(
as(resources(available(to(the(PNPCT(in(
order(to(confidently(recommend(and(
answer(patient(questions(regarding(CBD(
in(the(palliative(setting.
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Due(to(the(differences(in(legality(among(
states(about(MC(and(CBD,(HCP(may(be(
unaware(of(the(implications,(efficacy,(and(
resources(correlated(with(MC(and(CBD.(
Therefore,(patients(do(not(receive(
information(or(guidance(about(MC(as(a(
treatment(option(for(their(qualifying(
conditions.((
1.(What(is(MC,(specifically(CBD,
2.(Is(there(research(on(its(efficacy,
3.(Is(it(legal(in(all(states,
4.(How(would(providers(order(it,
5.(Would(it(show(up(on(a(drug(test,(and
6.(In(what(forms(is(CBD(available?
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The(analysis(of(the(survey(results(indicated(
the(participants(agreed(or(strongly(agreed(
that(the(content(met(the(objectives(and(was(
informative(to(their(practice.((
Participants(had(a(greater(understanding(of(
CBD,(awareness(of(the(physiology(of(CBD,(
efficacy(of(CBD,(and(knowledge(of(the(
resources(available(about(CBD.(
All(of(the(participants(were(engaged(and(had(
critical,(thoughtful(dialogue(about(CBD,(as(
well(as(found(the(topic(important(and(
pertinent(to(providing(holistic(patient(care.
Discussion(themes(included:
• how(to(recommend(CBD(to(their(patients,(
• how(to(incorporate(a(recommendation(in(
a(provider(note,(and
• dosage(strengths(for(their(patient(
population.
Overall,(this(project(led(to(an(
increased(awareness(amongst(the(
PNPCT(about(the(role(of(CBD(and(MC(
in(patient(care(and(healthcare.

